Company Filing History:
Years Active: 1998
Title: Innovations by Inventor Nicholas G. Galakatos in the Field of C5a Receptor Antagonists
Introduction
Nicholas G. Galakatos, an esteemed inventor based in Summit, NJ, has made significant contributions to the field of biotechnology through his innovative work on C5a receptor antagonists. With two patents to his name, his research focuses on developing therapeutic solutions for diseases associated with C5a-mediated inflammation.
Latest Patents
Galakatos's latest patents revolve around groundbreaking discoveries in DNA encoding for C5a receptor antagonists. His innovative work involves polypeptide analogues of human C5a, which are designed to act as receptor antagonists without exhibiting anaphylatoxin or agonist activity. His patents provide methods for creating these analogues and their derivatives, as well as dimeric forms. Furthermore, the pharmaceutical formulations developed from these analogues are intended for therapeutic use in treating C5a-mediated diseases and inflammatory conditions in mammals. The inclusion of specific antibodies targeting these C5a analogues allows for enhanced detection and quantification of circulating derivatives, contributing to improved clinical applications and treatment scenarios.
Career Highlights
Nicholas G. Galakatos has established a noteworthy career at Ciba-Geigy Corporation, a respected player in the pharmaceutical and biotechnology industry. His commitment to research and development is evident through his innovative patent applications, reflecting his dedication to advancing medical science and therapeutic practices.
Collaborations
Collaborating with notable colleagues such as Jan van Oostrum and William C. Boyar, Galakatos has contributed to a vibrant research environment that fosters innovation. These partnerships enhance the exploration of novel therapeutic avenues and solidify the impact of his work on the global stage.
Conclusion
Nicholas G. Galakatos stands out as a dynamic inventor whose work on C5a receptor antagonists has the potential to transform treatment strategies for inflammatory diseases. His patents demonstrate a commitment to advancing medical knowledge and improving patient outcomes, solidifying his position as a key figure in the biotechnology community.